Science For A Better Life

Science For A Better Life Investor Presentation FY/Q4 2007

Important Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forwardlooking statements or to conform them to future events or developments.

Transformation process has paid off Successful strategy reiterated Record performance in 2007 Strong outlook for 2008 and beyond Bayer Investor Handout Q4'07 March 08 (II) Page 1 The New Bayer A Leader in its Markets Pharmaceuticals 10.3bn Rx specialty pharmaceuticals, global # 6 34% 33% 19% 19% CropScience 5.8bn agrochemicals and seeds business, global # 1 in agrochemicals 33% Consumer Health 4.5bn OTC pharmaceuticals, blood glucose meters and veterinary medicines, global # 2-4 Bayer Investor Handout Q4'07 March 08 (II) Page 2 14% 15% 33% Group 32.4bn 2007 sales Material Science 10.4bn polyurethanes and polycarbonate business, global # 1 Break-down excluding reconciliation sales

Transformation Strategy Has Clearly Paid Off Achievements between 2002 and 2007 Delivering growth and performance Attractive returns over cost of capital at record levels Underlying EBIT quintupled from 0.8bn to 4.3bn Improved underlying EBITDA margin by 9 percentage points to 21% Improving portfolio Portfolio balance shifted towards HealthCare (from 32% to 48%) Rx and OTC pharmaceuticals businesses doubled in size Now market leader in agrochemicals All mature chemicals activities exited in several stages Developing new growth opportunities Developed a pharma pipeline with the potential to transform the business 1.4bn sales with new CropScience products (yoy +33%) Material Science business expanded into China Bayer Investor Handout Q4'07 March 08 (II) Page 3 Bayer s Transformation A Period of Significant Progress In million Sales EBIT underlying EBITDA margin reported*/ underlying 29,624 32,385 14,807 14,079 3,304 Chemicals 10,435 4,287 9,372 2,492 10,775 Polymers 716 4,697 5,826 786 578 14* 26 11* 23 12* 15-175 1,117 828 12* 21 2002 2007 2002 2007 2002 2007 Material HealthCare CropScience Industrials Science 2002 Group 2007 Bayer Investor Handout Q4'07 March 08 (II) Page 4 All 2002 numbers as restated in 2003, except Industrials and Group EBITDA (as reported in 2002)

Attractive Returns Over Cost of Capital CFRoI 10 hurdle 9 CFRoI % 13 12 11 8 7 6 10.4 9.8 9.9 10.2 8.0 9.2 9.9 12.4* 9.7 12.1 10.0 12.2 Value Generation in 2007 CVA of 749m CropScience and MaterialScience exceeded their target returns CFRoI is the ratio of gross cash flow to capital invested ( 39.2bn) CFRoI-hurdle (10.2%) is the minimum return required to cover cost of capital and reproduction of depletable assets Group WACC at 7.5% 2002 2003 2004 2005 2006 2007 Bayer Investor Handout Q4'07 March 08 (II) Page 5 *CFRoI as reported in 2005, 12.5% if portfolio adjusted Portfolio Balance Clearly Shifted Towards HealthCare 2001 Sales 30.3bn 2007 Sales 32.4bn HealthCare CropProtection Polymers H.C. Starck Wolff Walsrode Diagnostics Plasma Bayer Generics Household insecticides BCS antitrust requirements PolymerLatex H.C. Starck Wolff Walsrode Divestitures 14 bn Acquisitions 28 bn Schering AG + Roche OTC + Citracal + Pritor Europe + Levitra ex-usa + Possis Medical* + Aventis CropScience + Stoneville Cotton Seeds + Gustafson Seed Treatment + HealthCare CropScience Lanxess Lanxess Haarmann & Reimer Haarmann & Reimer Agfa stake Agfa interest GE Bayer Silicones GE Bayer Silicones interest Real estate Real estate Headcount 116,900 Bayer Investor Handout Q4'07 March 08 (II) Page 6 Transaction volume Major examples only MaterialScience Headcount 106,200 *pending

Portfolio Balance Clearly Shifted Towards HealthCare 2001 Sales 30.3bn 2007 Sales 32.4bn Diagnostics HealthCare Plasma 32% Bayer Generics Household insecticides CropProtection 16% BCS antitrust requirements Polymers 37% Others 15% PolymerLatex H.C. Starck Wolff Walsrode Lanxess Haarmann & Reimer Agfa interest GE Bayer Silicones interest Real estate Headcount 116,900 Bayer Investor Handout Q4'07 March 08 (II) Page 7 Divestitures 14 bn Acquisitions 28 bn Transaction volume Schering AG + Roche OTC + Citracal + Pritor Europe + Levitra ex-usa + Possis Medical** + Aventis CropScience + Stoneville Cotton Seeds + Gustafson Seed Treatment + Major examples only HealthCare 48%* CropScience 19%* MaterialScience 33%* Headcount 106,200 *excluding Reconciliation sales **pending Bayer s Successful Strategy Strategic Direction Transaction Financing Deliver growth and performance Strengthen HealthCare Stay in CropScience, continue to explore opportunities in seeds Stay in MaterialScience, organic growth as priority Develop new growth opportunities Balanced mix of debt, equity and portfolio if needed Maintaining single A credit rating target Probable Timing Steady monitoring and active management. Acquisitions and disposals are therefore part of our regular business activities Bayer Investor Handout Q4'07 March 08 (II) Page 8

Mid-term Financial Targets Underlying EBITDA margin Bayer HealthCare around 28% in 2009 Bayer CropScience Bayer MaterialScience approximately 25% in 2009 >18% under favorable economic conditions Group exceed 22% in 2009 Bayer Investor Handout Q4'07 March 08 (II) Page 9 Record performance in 2007 Bayer Investor Handout Q4'07 March 08 (II) Page 10

20 Consecutive Quarters With Y-o-Y Underlying EBIT Improvement 1,375 Underlying EBIT in million 4,287 1,236 1,142 1,185 3,479 3,300 841 827 90* 483 928 852 660 120** 458 953 798 691 774 622 615 2,244 1,466 336 383 374 828 125 68-59 42 '02 '03 '04 '05 06 07 '02 '03 '04 '05 '06 '07 '02 '03 '04 '05 '06 '07 '02 '03 '04 '05 '06 '07 '02 '03 '04 '05 '06 '07 Q1 Q2 Q3 Q4 FY Bayer Investor Handout Q4'07 March 08 (II) Page 11 2002 underlying EBIT as reported in FY 2003 2003 underlying EBIT as restated in 2004 2004-2007 underlying EBIT as reported in respective years * Including 90m EBIT from divested products ** Including 120m reversal of pension provisions FY 07 Financial Highlights in million FY 06 FY 07 Δ Sales 28,956 32,385 + 12% HealthCare 11,724 14,807 + 26% CropScience 5,700 5,826 + 2% MaterialScience 10,161 10,435 +3% EBITDA underlying 5,584 6,777 + 21% HealthCare 2,613 3,792 + 45% CropScience 1,204 1,324 + 10% MaterialScience 1,677 1,606-4% EBIT underlying 3,479 4,287 + 23% Non-operating result (782) (920) Net income 1,683 4,711 + 180% Core EPS (in ) 2.99 3.80 + 27% Net cash flow 3,928 4,281 + 9% Bayer Investor Handout Q4'07 March 08 (II) Page 12

Further Strategic Progress in 2007 Integration of Schering Strengthen HealthCare Seeds & traits expansion Synergy target raised to > 800m Expect 80% completion in 2008 Acquired calcium supplement brand Citracal Possis Medical - mechanical thrombectomy devices (pending) Inlicensed rthrombin, inhaled Amikacin Acquired US cotton seed company Stoneville Expanded reach of Liberty Link-technology into corn and soy Restructuring actions Disposals New 300m program initiated at MaterialScience Total volume of all programs now ~ 1bn (incl. SCHG) in 2008-2009 Professional Diagnostics, H.C. Starck and Wolff Walsrode closed Sale of Hennecke, a polyurethane processing machinery company Deleveraging Reduced net debt by 5.4bn in 2007 Bayer Investor Handout Q4'07 March 08 (II) Page 13 Q4 2007 Upward Trend Unabated In million, Δ% y-o-y Key Figures Underlying EBITDA by Subgroup excl. Reconciliation Sales 8,040 EBITDA* 1,422 EBIT* 774 Core EPS 0.71 Material Science HealthCare 25% Δ% + 1% +13% ² + 24% Δ% Adj. ** + 5% +42% 12% CropScience 63% * Before special items ** Currency & portfolio adjusted Bayer Investor Handout Q4'07 March 08 (II) Page 14

HealthCare Strongest Quarter in Terms of Sales in 2007 Q4 07 Sales Earnings In million, Δ% y-o-y Consumer Health +9% (+12%) Pharma -3% (+2%) Underlying EBITDA 796 922 +16% Underlying EBIT 1,181 563 670 +19% 461 584 +27% 2,619 263 367 +40% 233 252 +8% 198 217 +10% HealthCare 3,800m; +1% (+5%) Q4 06 Q4 07 Q4 06 Q4 07 ( ) Currency & portfolio adjusted Bayer Investor Handout Q4'07 March 08 (II) Page 15 CropScience Solid Business Expansion Q4 07 Sales Earnings In million, Δ% y-o-y Environmental Science/ BioScience +4% (+9%) Crop Protection +1% (+4%) 221 Underlying EBITDA 142 177 25 % Underlying EBIT 1,100 111 147 +32% 43 33 31 30-3% 0 11 10-9% -11 CropScience 1,321m; +2% (+5%) Q4 06 Q4 07 Q4 06 Q4 07 ( ) Currency & portfolio adjusted Bayer Investor Handout Q4'07 March 08 (II) Page 16

MaterialScience Margins up on Higher Prices Q4 07 Sales Earnings In million, Δ% y-o-y Systems +1% (+5%) 1,801 778 Materials +4% (+8%) Underlying EBITDA 307 62 245 325 367 +20% 42-32% +33% Underlying EBIT 187 18 169 240 241 +29% 1-94% +42% MaterialScience 2,579m; +2% (+6%) Q4 06 Q4 07 Q4 06 Q4 07 ( ) Currency & portfolio adjusted Bayer Investor Handout Q4'07 March 08 (II) Page 17 Q4 07 Cash Flow and Net Debt Q4'07 Cash Flow Net Debt Development In million In billion GCF NCF cont. Investments ofcf -0,5 1,021 1,467 737 732 12.7 12.2 Δ % y-o-y +34% -2% -7% -7% Q3 07 Q4 07 Bayer Investor Handout Q4'07 March 08 (II) Page 18

Strong outlook for 2008 and beyond Bayer Investor Handout Q4'07 March 08 (II) Page 19 Optimistic About Future Developments 2008 sales and earnings expectations and beyond Group Fx adj. sales increase by 5% Increase in underlying EBITDA and margin* HealthCare Fx adj. growth in all divisions at or above market Margin* increase toward 27% CropScience Fx adj. growth of 5% Margin* increase above 23% MaterialScience Higher volumes and good, value-creating earnings level, but below 2007. Q1 08 underlying EBITDA approx. at Q4 07 level. Group >22% margin* by 2009 HealthCare ~28% margin* by 2009 CropScience ~25% margin* by 2009 MaterialScience Attractive premium over capital and asset reproduction costs even in difficult market environment. Margin* in excess of 18% under favorable economic conditions. Bayer Investor Handout Q4'07 March 08 (II) Page 20 * Underlying EBITDA margin

Bayer HealthCare Bayer Investor Handout Q4'07 March 08 (II) Page 21 Bayer HealthCare has Defined its Aspirations Be one of the world s leading diversified healthcare companies Strengthen Pharma with focus on specialty Achieve above market growth and profitability and aspire for leading position in each market segment in which we compete Bayer Investor Handout Q4'07 March 08 (II) Page 22

We are Delivering Against these Aspirations Achievements Delivering growth and performance Ranked 2-4 in all businesses, except pharma (no.6* in specialty) Achieved targets to grow with all divisions at or above the market in 2007 On track towards our target of ~28% underlying EBITDA margin in 2009 Improving our portfolio Acquired Schering, 70% of Pharma revenues generated by specialty products Strengthened Consumer Health: Roche OTC, Metrika, Citracal, Sagmel Medrad offer for Possis Medical Developing new growth opportunities Developed a late stage pipeline with the potential to transform the business Aggressive growth strategy for emerging markets in place Inlicensed VEGF-Trap-Eye, rthrombin, Amikacin inhale * based on 2006 data Bayer Investor Handout Q4'07 March 08 (II) Page 23 Bayer HealthCare s Transformation A Period of Significant Progress 14,807 In million Sales EBIT underlying 9,372 2,492 EBITDA margin reported*/ underlying 716 14* 26 2002 2007 HealthCare Bayer Investor Handout Q4'07 March 08 (II) Page 24

Achieved Targets and Significantly Improved Performance in 2007 FY 07 Sales Earnings In million, Δ% y-o-y Consumer Health +7% (+10%) Pharma +37% (+6%) Underlying EBITDA 3,792 +45% Underlying EBIT 4,540 2,613 2,807 +67% 2,492 +45% 10,267 1,686 927 985 +6% 1,715 1,641 +76% 934 781 851 +9% HealthCare 14,807m, +26% (+7%) FY 06 FY 07 FY 06 FY 07 ( ) Currency & portfolio adjusted 22.3 25.6 14.6 16.8 Bayer Investor Handout Q4'07 March 08 (II) Page 25 Underlying EBITDA margin Underlying EBIT margin The TOP-15 HealthCare Products Collectively grew 8% in 2007 Product Indication Sales 2007 Yasmin / Yaz / Yasminelle Oral Contraception 1,042 Bayer Investor Handout Q4'07 March 08 (II) Page 26 Δ y-o-y Fx adj. +37 %* Betaferon / Betaseron Multiple Sclerosis 1,028 +7 %* Ascensia family Blood Glucose Monitoring 934 +24 % Kogenate Hemophilia A 818 +8 % Aspirin family Pain, Cardio CC 689 +6 % Adalat Hypertension, CHD 614-2 % Avalox / Avelox Antibiotic 445 +17 % Cipro / Ciprobay Broad Spectrum Antibiotic 383-23 % Mirena Contraception 361 +25 %* Levitra Erectile Dysfunction 332 +11 % Advantage product line Pet-Parasiticide 314 +21 % Magnevist MRI Diagnosis 301-1 %* Glucobay Type II Diabetes 298 +1 % Nexavar Kidney Cancer/Liver Cancer 270 +116 % Aleve Analgesic 239 +14 % *pro-forma

Global Leader in Specialty Pharmaceuticals Pharmaceuticals 10.3bn Rx specialty pharmaceuticals, # 6 with leading positions in key therapeutic categories 17% 18% 6% Consumer Care 2.6bn OTC pharmaceuticals; # 2 with some of the world s most recognized brands Diabetes Care 950m blood glucose meters # 3-4 with new and improved products 71% 70% 6% Animal Health 956m veterinary medicines # 4 with leading growth and profitability Key figures 2007 Sales: 14.8bn EBITDA underlying: 3,792m (margin 25.6%) Employees: ~51,000 Bayer Investor Handout Q4'07 March 08 (II) Page 27 Integration of Schering Continues to Progress Well Savings by function Procurement & Manufacturing ~20% ~15% ~35% R&D Synergy target raised from originally 700m to > 800m primarily from R&D and G&A 80% expected to be realized by yearend 2008 Marketing & Sales ~30% Net integration costs* of approx. 1bn** assumed G&A * excluding work-down of step up of inventories and impact of purchase price allocation ** 2006: 179m, 2007: 506m, 2008e: ~ 200m Bayer Investor Handout Q4'07 March 08 (II) Page 28

We can report important pipeline advancements since our HealthCare Day in June 2007 4 approvals Nexavar HCC RECOTHROM (U.S.) Campath 1 st line chronic B-CLL Primovist MRI (J) 3 submissions for regulatory approval Xarelto VTE prevention (EU) DUB-OC oral contraception (EU) Zevalin: 1st line consolidation foll. Lymphoma (EU) 5 new phase III projects 5 new phase II projects 2 new phase I projects Bayer Investor Handout Q4'07 March 08 (II) Page 29 and Expect Numerous Projects To Enter Phase III Over the Next 18 Months Project Indication Expected start of phase III Estimated launch FC Patch Contraception 1H 2008 > 2012 Vardenafil (ODT) Erectile Dysfunction 1H 2008 Tbd. rthrombin Surgical Hemostasis (EU) 2H 2008 2010 Amikacin inhaled Ventilator Associated Pneumonia 2H 2008 2011 Vardenafil Overactive Bladder 2H 2008 2011 sgc Stimulator Pulmonary Hypertension 2H 2008 2011 Ciprofloxacin inhaled Bacterial Infections 1H 2009 2011 ZK-EPO Solid Tumors 1H 2009 > 2012 Kogenate liposomal Hemophilia A 2H 2009 2011 Spheramine sgc Activator Rivaroxaban Parkinsons Disease Acute Heart Failure Acute Coronary Syndrome 2H 2009 2H 2009 2H 2009 2012 2012 > 2012 Nexavar Breast Cancer 2H 2009 > 2012 Bayer Investor Handout Q4'07 March 08 (II) Page 30

Our R&D Pipeline Provides a Balanced Mix of NME and LCM Opportunities Phase I Phase II Phase III Submitted No. of projects PH in COPD Elastase Inhibitor Pancreatic Cancer / Melanoma L19 Interleukin 2 Cancer L19-SIP Colorectal Cancer L19-TNFalpha Breast Cancer Novel SERD ACS Dual FIIa/Xa Inhibitor Hypogonadism Treatment ef-ment Gastro IBD Lipoxin DME VEGF Trap-Eye Alzheimer PET Imaging AV1/ZK Cancer DAST Inhibitor Menopausal Management ERß Agonist Fast Dissolving Tablet Levitra 13 19 A fib / Stable Angina Adenosine A1 Agonist Acute Heart Failure sgc Activator Pulmonary Hypertension sgc Stimulator ACS Rivaroxaban RCC 1st / 3rd line L19 Interleukin 2 Breast Cancer ZK-PRA Lung / Ovar / Breast / Prostate Sagopilone (ZK-EPO) Parkinson s Disease Spheramine Heart Failure sgc Stimulator Gram-neg. VA Pneumonia Amikacin inhaled (NKTR-061) Liposomal Formulation Kogenate Breast Cancer Nexavar Additional Indications Nexavar Fertility Control FC Patch Fidencia New Indications Vardenafil Lung Infection Cipro inhaled OC E2+DRSP OC OC+DHEA OC Valette plus Medical ill Rivaroxaban SPAF Rivaroxaban VTE Treatment Rivaroxaban wet AMD VEGF Trap-Eye Melanoma, 1st line Nexavar NSCLC, 1st line Nexavar Multiple Sclerosis Alemtuzumab Fertility Control YAZ Flex Menorrhagia Mirena Menopausal Management Angeliq low-low Endometriosis Visanne Fertility Control Yasmin plus / YAZ plus Fertility Control LCS (ULD LNG) 1st + 2nd line aggr. NHL Zevalin ACS Aspirin i.v. MRI (USA,Asia) Gadovist 21 8 CKD (J) Fosrenol VTE Prevention Rivaroxaban Bone Met. Prevent. in Breast Cancer Bonefos Dysmenhorrea (J) YAZ DUB DUB-OC (E2/DNG) CT Ultravist 370 New Indications (US) Avelox VMS Menostar transdermal HRT (J) E2 / LNG MRI (J) Magnevist MRA PID / New Indications (EU) Avelox 1st line indolent NHL Zevalin OC DUB-OC (E2/DNG) New Molecular Entities (NME) Life Cycle Management (LCM) Status as of Feb 28 2008 Bayer Investor Handout Q4'07 March 08 (II) Page 31 Anticoagulants A Large Unmet Medical Need Market Medical Need 2006 $5.3bn 0.6bn 0.7bn 0.2bn 3.8bn LMWHs UFH Vitamin K antag. Approximately 6.5 million people worldwide are affected annually by venous thromboembolism (VTE) Up to 600,000 people are hospitalized in the U.S. each year for deep vein thrombosis (DVT) 2016e $15.1bn 7.8bn 4.6bn 2.4bn 0.1bn 0.2bn Other injectables Novel oral anticoagulants Approx. 8.5 million suffering from atrial fibrillation (AFIB) in Europe, Japan and U.S. AFIB patient has a 5-fold higher risk of stroke events Source: IMS Bayer Investor Handout Q4'07 March 08 (II) Page 32

Xarelto (Rivaroxaban) Potentially Redefining the Market for Anticoagulants An ideal anticoagulant should have Xarelto has: Oral administration Once daily dosing Predictability Wide therapeutic window Minimal food/drug interactions No monitoring Bayer Investor Handout Q4'07 March 08 (II) Page 33 Convenient use both in and out of hospital Key issue to enhance compliance in the target population Safe and effective regulation of coagulation from the first dose and throughout therapy Broad safety margin at a wide range of effective doses Ease of use with concomitant medication and diet No need for laboratory monitoring saves healthcare costs through fewer hospital / physician visits and patients time based on current knowledge Comprehensive Late-Stage Development Program for Xarelto in Place Trial title Indication and study size Expected Filing Phase III Phase III VTE Prevention in patients undergoing major orthopedic surgery: >12,000 patients VTE Treatment and long-term secondary prevention: ~7,500 patients Filed in EU; U.S. mid 2008 2010 Phase III Phase III Prevention of stroke in patients with atrial fibrillation: ~14,000 patients VTE Prevention in hospitalized acute medically ill patients: ~8,000 patients* 2010 2011 *expected Phase II Secondary prevention of fatal and non-fatal cardiovascular 2012 ~ events in patients with acute coronary syndrome (ACS): ~3,500 patients Bayer Investor Handout Q4'07 March 08 (II) Page 34

Pivotal Phase III Data Show Superior Efficacy of Xarelto over Enoxaparin* Double-blind, randomized, controlled phase III study for VTE Prevention in elective total knee or hip replacement patients vs. enoxaparin Xarelto consistently demonstrated superior efficacy vs. existing standard of care Xarelto has shown a safety profile with low bleeding rates similar to enoxaparin More than 14,000 patients have been exposed to Xarelto to date - no evidence of liver signal attributable to Xarelto observed No evidence of liver signal attributable to Xarelto in 2,400 patients treated for 3-6 months More definite statement on safety can be made upon availability of data from long term exposure to Xarelto *Published at ASH in Dec. 2007 Submitted for VTE prevention in EU in October 2007. RECORD4 data planned to be presented at EFORT (May 29 June 1, 2008) in Nice. Bayer Investor Handout Q4'07 March 08 (II) Page 35 The RECORD 1-3 Studies Show Superior Efficacy over Established Standard of Care Indication VTE Prevention in patients undergoing total hip replacement VTE Prevention in patients undergoing total hip replacement VTE Prevention in patients undergoing total knee replacement Trial Design 4,541 patients 10mg od* Xarelto for 5 weeks vs. 40mg od* enoxaparin for 5 weeks 2,509 patients 10mg od* Xarelto for 5 weeks vs. 40mg od* enoxaparin for 10-14 days followed by placebo 2,531 patients 10mg od* Xarelto for 10-14 days vs. 40mg od* enoxaparin for 10-14 days Efficacy Xarelto Enoxaparin p Xarelto Enoxaparin p Xarelto Enoxaparin p Composite of DVT, PE and all cause mortality Rel. risk reduction Major VTE Rel. risk reduction 1.1% 3.7% <0.001 70% 0.2% 2.0% <0.001 88% 2.0% 9.3% <0.001 79% 0.6% 5.1% <0.001 88% 9.6% 18.9% <0.001 49% 1.0% 2.6% 0.016 62% Safety Xarelto Enoxaparin p Xarelto Enoxaparin p Xarelto Enoxaparin p Major bleeding Non-major bleeding 0.3% 0.1% 0.178 5.8% 5.8% 1.000 0.1% 0.1% 0.980 6.5% 5.5% 0.246 0.6% 0.5% 0.774 4.3% 4.4% 0.990 *od = once daily Bayer Investor Handout Q4'07 March 08 (II) Page 36

Alemtuzumab (Campath) in B-Cell Chronic Lymphocytic Leukemia Campath How does Campath work? Humanized monoclonal antibody directed against the CD52 receptor found on B and T cells Treatment produces acute cytolysis in CD52 bearing cells via 3 immunemediated reactions Launched 2001 for treatment of B-Cell chronic Lymphocytic Leukemia (3rd line) Complement fixation CD52 Antibodydependent cell-mediated cytotoxicity Induction of apoptosis Approved by FDA as 1st line single agent B-CLL treatment Campath Approved in EU for 1st line therapy of B- CLL if fludarabine combination therapy is not appropriate Bayer Investor Handout Q4'07 March 08 (II) Page 37 Alemtuzumab Has Demonstrated Best Treatment Effects Ever Seen in a Controlled MS Trial so far In a two-year phase II interim analysis Alemtuzumab was significantly more effective than Rebif in suppressing MS relapses and slowing accumulation of disability in MS patients: Alemtuzumab dose Reduction in risk for relapse vs. Rebif Reduction in risk for progression of clinically significant disability New three-year top-line results presented at ECTRIMS 2007 were statistically significant confirming all trends of the one-year and two-year analyses, including the positive impact on disability Patients taking alemtuzumab experienced at least a 73 percent reduction in the risk for relapse and at least a 70 percent reduction in the risk for progression of clinically significant disability after three years of follow up Formal database lock of CAMS223 and report on further data expected at AAN in 2008 Immune Thrombocytopenic Purpura (ITP) 36 months update 6/216 patients treated with alemtuzumab developed ITP during the study No new cases of ITP in past one year Reduction in disability compared with pretreatment baseline (EDSS score) 12 mg 72% (p<0.0001) 88% (p<0.0008) Significant 24 mg 87% (p<0.0001) 66% (p<0.0098) Significant Bayer Investor Handout Q4'07 March 08 (II) Page 38

Alemtuzumab Phase III in MS Initiated CARE-MS: Comparison of Alemtuzumab and Rebif Efficacy in MS CARE-MS I Early active RRMS Up to 525 treatment naïve patients Alemtuzumab 12mg vs. Rebif 44mcg CARE-MS II RRMS in patients previously treated with disease modifying therapy Approx. 1,200 patients Alemtuzumab 12mg and 24mg vs. Rebif 44mcg Randomized, open label, active control studies Treatment Duration: 2 years after last patient is enrolled Primary Outcome Measure: Time to sustained accumulation of disability (SAD) Relapse Rate Filing of Alemtuzumab in MS planned for 2011 Overall efficacy and safety observed in phase II study to be established and confirmed in the phase III program Bayer Investor Handout Q4'07 March 08 (II) Page 39 VEGF TRAP-Eye Underscores our Specialty Focus Market / Indication VEGF Trap-Eye program Wet AMD due to abnormal blood vessel growth in the eye; accounts for approx. 90% of AMD-related blindness Additional opportunities in other eye diseases Indications: wet age-related macular degeneration (AMD) and diabetic macular edema (DME) Mechanistic basis: inhibition of VEGFmediated neovascularization Phase III for wet AMD initiated in August 07 Collaboration with Regeneron Pharmaceuticals Bayer Investor Handout Q4'07 March 08 (II) Page 40

VEGF Trap-Eye Phase III in wet AMD Initiated VIEW 1: VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration Randomized, double-blind, active control study Evaluating the safety and efficacy of VEGF Trap-Eye compared to ranibizumab Dosing: VEGF Trap Eye Ranibizumab 0.5mg and 2.0mg 0.5mg four-week dosing intervals four-week dosing intervals 2.0mg eight-week dosing interval 1,200 patients to be enrolled Primary outcome measure: Visual acuity changes compared to baseline (ETDRS) Launch in wet AMD estimated in 2012 VEGF Trap-Eye is targeting the leading cause of age related blindness Bayer Investor Handout Q4'07 March 08 (II) Page 41 Continue to Further Strengthen our Pipeline Through Improved Inlicensing Capabilities RECOTHROM (ZymoGenetics) Amikacin inhale (Nektar) Recombinant version of thrombin (bloodclotting factor IIa) Indication: surgical hemostasis Comparable efficacy to bovine-derived thrombin, reduced immunogenicity demonstrated in phase 3 studies FDA approval on January 17 2008 Bovine thrombin is used in more than 1 million surgeries in the U.S. per year Near-term revenue potential for our hematology business Proprietary drug delivery technology for inhalation of antibiotic amikacin deep into the lung Indication: Ventilator associated pneumonia Unmet medical need: significant morbidity and mortality with very limited treatment options today Currently in phase II clinical trials, phase III expected to start in 2008 Bayer Investor Handout Q4'07 March 08 (II) Page 42

Global Leader in Consumer Health Pharmaceuticals 10.3bn Rx specialty pharmaceuticals, # 6 with leading positions in key therapeutic categories 71% 70% 17% 18% 6% 6% Consumer Care 2.6bn OTC pharmaceuticals; # 2 with some of the world s most recognized brands Diabetes Care 950m blood glucose meters # 3 with new and improved products Animal Health 956m veterinary medicines # 4 with leading growth and profitability Key figures 2007 Sales: 14.8bn EBITDA underlying: 3,792m (margin 25.6%) Employees: ~51,500 Bayer Investor Handout Q4'07 March 08 (II) Page 43 Consumer Health: Key Growth Drivers Attractive underlying trends Aging population and increasing life expectancy Shifting costs to consumers: OTC affordable alternate Health becoming more consumer-centric Evolution from passive patient to pro-active consumer Consumer business financially attractive Predictable sales with attractive growth rates and modest risk Consumer investments build long-term sustainable brands Not patent dependent Less R&D and capital intensive Strong consumer brands have extremely long lifetimes Driving growth of strong brands Estimated 80% of market growth will be behind existing brands Bayer Investor Handout Q4'07 March 08 (II) Page 44

Consumer Health Achieved Significant Growth Rates In million 4,246 4,540 Consumer Health yoyfxadj. 2,531 2,634 + 8% Consumer Care 781 851 +9% 810 950 + 23% Diabetes Care 905 956 + 11% Animal Health 2006 2007 Sales 2006 2007 Underlying EBIT Bayer Investor Handout Q4'07 March 08 (II) Page 45 We Consistently Built the Consumer Health Portfolio Sagmel Acquisition of OTC business of Sagmel, Inc. (Mar. 11, 2008) Strengthening of Consumer Care s presence in East Europe (Russia, Belarus, Ukraine and Kazakhstan) 2006/07 sales: 78m Acquisition of leading calcium brand enriches Consumer Care s key nutritionals product portfolio (Aug. 30, 2007) 2007 sales: US$47m Alliance with Medtronic to provide blood glucose meter to Medtronic patients outside the US (Aug. 21, 2007) Distribution and co-marketing of new meter, that wirelessly transmits test results to insulin pumps and monitoring systems. Acquisition of Western OTC Cough and Cold business of Topsun (Oct. 25, 2006; pending) Increase presence in China, one of the fastest growing OTC markets in the world 2005 sales: approx. 32.4m Bayer Investor Handout Q4'07 March 08 (II) Page 46

Consumer Care: Demonstrating Global Business Strength Key data Consumer Care OTC market size 56bn (in 2006) Market growth + 5% (2007 vs. 2006) From a mid-tier player in 1990s to top-tier now Consistently outpace market growth: 9 out of last 11 years One of fastest growing major players Bayer sales in 2007 Bayer sales growth (2007 vs. 2006, Fx adj.) 2.6bn + 8% Bayer Consumer Care growth +8% (Fx adjusted number) in 2007, vs. 5% market growth Bayer market position No. 2 Bayer Investor Handout Q4'07 March 08 (II) Page 47 Diabetes Care: Operating in a Very Attractive, Growing Market Key data Diabetes Care Market size 5.6bn (in 2006) Market growth + 7% (2007 vs. 2006) Bayer sales in 2007 950m Bayer sales growth + 23% (2007 vs. 2006, Fx adj.) Bayer market position No. 3 Eight consecutive quarters of above market revenue growth (12 in international markets) Bayer surpassed Abbott as #3 in Q1 2007 Portfolio expansion with Metrika acquisition and new product launches Geographic expansion/investment in key emerging high growth markets India China Russia/CCEE Latin America Bayer Investor Handout Q4'07 March 08 (II) Page 48

Animal Health: Outpacing Market Growth Key data Animal Health Market size 13bn (in 2006) Market growth + 3% (2007 vs. 2006) Bayer sales in 2007 956m Bayer sales growth + 11% (2007 vs. 2006, Fx adj.) Bayer market position No. 4 Outpaced market growth Ranked #3 in Companion Animal Products (13% ms) Well positioned in fast growing and profitable market segment 22% market share in parasiticides Ranked #6 in Food Animal Products (5% ms) Strong position in parasiticides and quinolone anti-infectives Bayer Investor Handout Q4'07 March 08 (II) Page 49 Consumer Health: Attractive Growth Targets Consumer Care Diabetes Care Animal Health Capitalize on consistent market growth outperformance Growth through building strong brands Growth through innovation Switching opportunities U.S. OTC Pravachol rights Expansion into high growth regions Turnaround strategy resulting in market leading growth Investing in brand-building, entering new markets Shortening life cycles: >75% of products younger than 3 years by 2009 Pursuing partner of choice approach Build on benchmark performance Excellent life cycle opportunities including new innovative formulations Rich pipeline target is to generate 25% of sales with new products by 2010 Target 2%pts. above market growth expected at 3 4% Target 2 3%pts. above market growth expected at 6 7% Target 2%pts. above market growth expected at 3 4% Bayer Investor Handout Q4'07 March 08 (II) Page 50

HealthCare Profitability Targets Underlying EBITDA margin targets 2008 HealthCare towards 27% (updated after Yasmin trial decision) 2009 HealthCare around 28% (confirmed) Aspire to further improve profitability longer-term Bayer Investor Handout Q4'07 March 08 (II) Page 51 Bayer CropScience Bayer Investor Handout Q4'07 March 08 (II) Page 52

2007 A Year of Significant Progress +6% 1 business expansion despite patent expiry of Imidacloprid New product sales 2 +33% to 1.4bn Seed treatment business hiked substantially to 605m 130m fresh savings from restructuring generated Underlying EBITDA margin up 160 basis points to 22.7% Strengthened seed business Strong outlook: targeting 5% 3 business expansion and increase of underlying EBITDA margin to above 23% Successful start into 2008 1 currency and portfolio adjusted 2 new active ingredient launched since 2000 3 currency adjusted Bayer Investor Handout Q4'07 March 08 (II) Page 53 Financial Highlights 2007 Sales 2007 Earnings In million, Δ% y-o-y Environmental Science/ BioScience -1% (+3%) 1,045 Crop Protection +3% (+6%) Underlying EBITDA 1,204 927 1,324 +10% 1,093 +18% Underlying EBIT 641 786 +23% 4,781 441 632 +43% 277 231-17% 200 154-23% CropScience 5,826m, +2% (+6%) 2006 2007 2006 2007 ( ) Currency & portfolio adjusted 21.1% 22.7% Underlying EBITDA margin Bayer Investor Handout Q4'07 March 08 (II) Page 54

New Products Drive Business Expansion (In million) FY 2007 YOY YOY Fx Imidacloprid 556-1.4 % 1.6 % Trifloxystrobin 243 34.3 % 36.7 % Glufosinate-ammonium 241 5.2 % 10.2 % Clothianidin 237 86.6 % 98.1 % Tebuconazole 235-14.9 % -13.6 % Mesosulfuron 207 22.5 % 23.1 % Fenoxaprop-p ethyl 187-4.6 % -2.0 % Deltamethrin 178-2.7 % 0.4 % Prothioconazole 175 21.5 % 22.3 % Ethofumesate / DMP / PMP 127 5.8 % 8.2 % Total Top 10 Products 2,386 9.0 % 12.0 % New Active Ingredient Fx = currency adjusted Bayer Investor Handout Q4'07 March 08 (II) Page 55 Attractive Opportunities in Ag Market Increasing demand for food, feed, fiber and biofuels drive commodity prices at record highs Acreage expansion and higher investments in crop protection, yield increase and higher quality products Innovative solutions required for yield increase, stress tolerance and resistance management, which can claim price premiums Demand for biofuel crops boosts crop protection and seeds & traits markets Increased acceptance and penetration of transgenic crops Bayer Investor Handout Q4'07 March 08 (II) Page 56

Commodity Prices Expected to Remain on High Level Commodity price development of key crops US-$/ton 600 500 400 300 200 Soybean Rice Wheat Corn Production of key crops wheat, corn and rice fell significantly short of consumption in the 2006/07 growing period Decline of global grain stock levels expected to continue well into 2009 100 0 2005 2006 2007 2008e 2009e Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Supply/demand balance anticipated to remain tight Source: The Economist Intelligence Unit, August 2007 and February 2008 Bayer Investor Handout Q4'07 March 08 (II) Page 57 CropScience: Strategic Priorities Drive Top-line in Agrochemicals Deliver strong pipeline of new active ingredients Exploit opportunities from growing demand for biofuel Expand Seeds and Traits Business Grow successful platform of canola, cotton, rice and vegetables Leverage our proprietary trait assets Intensified focus on the research areas yield increase and stress tolerance Improve Profitability Execute restructuring and generate targeted cost savings Improve product mix Bayer Investor Handout Q4'07 March 08 (II) Page 58

New Products Drive Improvement of Product Mix Sales of new a.i.s Share of new a.i.s in agchem sales In million +33 % 1,384 Insecticides Seed Treatment Herbicides Fungicides 1,039 19 % 25%* 2006 2007 2006 2007 Agchem sales: include Crop Protection and Environmental Science, exclude BioScience business * Crop Protection only: 28.5 % in FY'07 Bayer Investor Handout Q4'07 March 08 (II) Page 59 Promising Crop Protection Pipeline Research Early development Advanced development (Pre-) Launch already launched Launch (E) 2015 2013-2015 2008-2012 2007-2008 2000-2006 Total 45 Projects 9 A.I.s 9 A.I.s 4 A.I.s 17 A.I.s Herbicides* 4 2 5 Fungicides** 42 8 4 6 Insecticides** 1 2 6 Plant Health 3 1 * incl. safeners ** including seed treatment applications Peak sales potential of 2bn from 26 new active ingredients targeted by 2011 Bayer Investor Handout Q4'07 March 08 (II) Page 60

Bayer CropScience Portfolio for Biofuel Crops Bioethanol Corn Distinguished seed treatment portfolio headed by Poncho LibertyLink technology for corn seed Cereals Innovative cereal herbicides (e.g. Atlantis) and fungicides (e.g. Proline, Fandango) Sugarcane Well-proven and novel crop protection solutions (e.g. Evidence, Provence) Biodiesel Canola High yielding hybrid seed InVigor combined with herbicide-tolerant trait and crop protection products Soybean Extensive fungicide portfolio (e.g. Folicur, Flint) and seed treatment solutions LibertyLink technology for soybean seed Jatropha Project to develop and register crop protection solutions for use in Jatropha Bayer Investor Handout Q4'07 March 08 (II) Page 61 Growing Demand for Biofuel Boosts Crop Protection and Seeds & Traits Market Market size in million 5,000 CAGR 2006-2015e (total): + 11 % 4,000 3,000 2,000 1,000 0 2006 2007e 2008e 2009e 2010e 2011e 2012e 2013e 2014e 2015e Seeds & Traits for biofuel crops CAGR +12 % Crop Protection input for biofuel crops CAGR + 9 % Source: Bayer CropScience estimates Bayer Investor Handout Q4'07 March 08 (II) Page 62

Grow Successful Platform of Canola, Cotton, Rice and Vegetable Seeds Canola Cotton Rice Vegetables Launch of InVigor Health hybrid canola in alliance with Cargill Acquisition of Stoneville, CPCSD and Reliance Genetics Regional expansion (Indonesia, Vietnam, Brazil and Pakistan) Acquisition of Unilever s tomato seed business, SeedEx, Paragon Seed and Teboza Agreements with Senesco and Euralis Semences License agreement with Senesco 2 Joint ventures in China in process Regional expansion in Asia Pacific Investment of ~ 250m in seed business extension during past 12 months Targeting sales of ~ 1bn in BioScience within the next 10 years Bayer Investor Handout Q4'07 March 08 (II) Page 63 Expand Reach of LibertyLink Technology into Corn and Soy Growing weed resistance to glyphosate spurs market interest in our LibertyLink technology Liberty herbicide (glufosinate-ammonium) is effective on glyphosate-resistant weeds CropScience granted Monsanto a non-exclusive, royalty-bearing license to use LibertyLink technology in corn and soybeans Collaboration with Mertec and M.S. Technologies to develop and commercialize new herbicide tolerance traits in soybeans Expansion of production capacities for Liberty herbicide underway Potential for significant trait income and sales of our Liberty herbicide Bayer Investor Handout Q4'07 March 08 (II) Page 64

Promising BioScience Pipeline Research Early development Advanced development Prelaunch Launch (E) 2015 >2013 >2010 2009/2010 No. Projects ~30 5 6 3 Projects Herbicide- Herbicide- Herbicide- Herbicidetolerance tolerance tolerance tolerance: Insect- Insect- Insect- In-house GlyTol control control control (cotton) Quality traits Quality traits Cotton GlyTol x LL (cotton) Disease control Disease control Canola LL (soybean) Stress tolerance Soybean Yield increase Rice Bayer Investor Handout Q4'07 March 08 (II) Page 65 Restructuring Actions to Improve the Cost Base Savings contributions from our performance programs In million ~330 New initiative Challenge 2007 ~190 2005-2007 until 2009* * saving measures largely completed by 2009; full EBIT impact in 2010 Bayer Investor Handout Q4'07 March 08 (II) Page 66 Approx. 300m savings p.a. targeted with new efficiency initiative Expected cash charge of approx. 330m along with write-downs of about 120m Initiative expected to become mainly effective in 2009, accretive to EBIT starting 2008 In 2007 fresh savings of about 130m achieved; special items of approx. 100m Targeted fresh savings of about 60m in 2008 along with one-time charges in the range of 200m

Major Achievements since 2002 Underlying EBIT ( million) Underlying EBITDA margin (%) 11.1* -175 20.3 423 20.9 522 21.6 685 21.1 641 22.7 786 Successful integration of Aventis CropScience Significant earnings contribution from integration and efficiency programs Introduction of 19 new a.i.s since 2000 with sales of 1.4bn in 2007 Divestment / phase-out of older products Expansion of seeds and traits business 2002 2003 2004 2005 2006 2007 * reported EBITDA margin; as published in 2003 Bayer Investor Handout Q4'07 March 08 (II) Page 67 Optimistic About Future Developments 2008 Target Sales growth Fx adjusted around 5 percent Increase in underlying EBITDA margin to more than 23% 2009 Target Underlying EBITDA margin at around 25% (under normal market conditions) Bayer Investor Handout Q4'07 March 08 (II) Page 68

Bayer MaterialScience Bayer Investor Handout Q4'07 March 08 (II) Page 69 Bayer MaterialScience Focused on Polycarbonates and Polyurethanes Polyurethanes #1; approx. 25% market share Applications: mainly rigid and soft foams Coatings, Adhesives, Sealants #1; >40% market share (arom. and aliph. isocyanates) Applications: automotive & transport, construction, furniture & wood Total sales 10,435m 51% 27% 15% Bayer MaterialScience FY 2007 sales 2% 4% Polycarbonates #1; approx. 30% market share Main brand: Makrolon Applications: electro/electronics, construction, automotive, sports / leisure Thermoplastic Polyurethanes #1; approx. 20% market share Inorganic Basic Chemicals Internal supplier of chlorine, sodium hydroxide solution, hydrogen, hydrochloric acid Bayer Investor Handout Q4'07 March 08 (II) Page 70

Bayer MaterialScience Business Objectives Deliver Growth Maintain or expand market leadership positions Tap significant growth potential through business expansion in Asia Extend businesses further along the value chain Develop new products and applications Increase Efficiency Achieve savings of 300m annually by the end of 2009 Reduce organizational complexity Adopt business models with clearly differentiated marketing concepts and budgets Constantly improve production processes and focus on world-scale production Generate Value Earn a premium over capital and asset reproduction costs throughout the cycle Improve underlying EBITDA margin to >18% under favorable economic conditions Bayer Investor Handout Q4'07 March 08 (II) Page 71 Major Products Outpace GDP Growth Long-term Trend Intact Across The Cycle 100 Major product sales growth Polyurethanes and Polycarbonates +10% CAGR +3% CAGR Global GDP Index (real) Index 1992 = 100 Major long-term growth drivers: Construction > Energy saving > Heat insulation Automotive > New polymeric applications Innovation > Films/surfaces and nanotechnology 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 CAGR 1992-2007 Total net sales include Lyondell Polyols acquisition in 2000 Bayer Investor Handout Q4'07 March 08 (II) Page 72

China Outpaces Global Growth in Our Major Businesses PUR and PCS Polyurethanes consumption Polycarbonates consumption 2006 2010e In 1000 tons 2006 2010e + 5% CAGR + 8% CAGR 10,200 12,400 Global 2,900 3,900 + 9% CAGR + 18% CAGR 1,750 2,500 China 780 1,500 Bayer estimates, PCS incl. Blends, PUR incl. MDI, TDI and polyether polyols China is set to become the world s China already is the world s largest largest PUR market by 2015 PCS market today Bayer Investor Handout Q4'07 March 08 (II) Page 73 Construction of Bayer s Largest, Fully Integrated Polymer Site Under Way Strengthen our regional competitiveness through local production in China PUR PCS CAS Shanghai MDI 80 kt in 2006 (crude MDI splitter) 350 kt in 2008* TDI 300 kt in 2010** *under construction **planned All numbers are name plate capacities Dates refer to availability on stream PCS 40 kt in 2005 (PC compounding) PCS 100 kt in 2006 +100 kt in 2008* HDI 30 kt in 2006 +20 kt thereafter** PUD 20 kt in 2008** Desmodur N 12 kt in 2003 Expansion in 2008** Desmodur L 11 kt in 2004 10 kt in 2007 Bayer Investor Handout Q4'07 March 08 (II) Page 74

Focused Capital Investment in China CapEx on fixed assets 15% 10% 20% North America Competitive CapEx funding to secure long-term volume growth 25% 55% 30% 55% 25% 45% Europe Greater China Investment focus of approx. 1.8bn in China demonstrates commitment to participate in future growth of this region 5% 5% 10% ROW 2007 2008e 2009e All figures are approximations, plan based on 2008 budget Greater China: PR China, Taiwan, Hongkong Bayer MaterialScience capital expenditures efficiently deployed Bayer Investor Handout Q4'07 March 08 (II) Page 75 300m Restructuring Initiatives Reduce Costs and Realign Organization Phasing of realized savings and related costs splits roughly equally between 2008 and 2009 Savings by functions in 2009 Related special charges expected at 150 200m Process and cost optimization in the operation and maintenance of production facilities worldwide Realigned business models (bulk vs. downstream) with clearly differentiated marketing concepts and budgets ~ 300m Significant reduction of G&A costs through reduced complexity of corporate structures Reduction of personnel costs by cutback of about 1,500 positions worldwide Manufacturing and Procurement Marketing and Sales General and Administration Research and Development Bayer Investor Handout Q4'07 March 08 (II) Page 76

We Are Generating Attractive Premiums Over Our Capital and Asset Reproduction Costs Value Generation in 2007 in bn 1.5 1 0.5 CFRoI 10.3% 9.1% CFRoI hurdle 0.9 0.2 16.4% 9.0% 1.4 0.7 15.6% 8.7% 1.2 0.5 15.9% 8.1% 1.2 0.3 in % 17 15 13 11 9 7 Cash Value Added (CVA) of 604m generated (2006: 517m) CFRoI of 15.9% well exceeded hurdle in fourth consecutive year CFRoI hurdle of 8.1% represents minimum requirement that covers cost of capital and reproduction of depletable assets (2005: 8.7%) Subgroup WACC at 6.5% Gross cash flow Operating free cash flow 2004 2005 2006 2007 2004 and 2005 as reported in 2005 Bayer Investor Handout Q4'07 March 08 (II) Page 77 Good, Value-Creating Earnings Level In million EBITDA margin (underlying) 14.5 668 293 375 18.2 16.5 1,404 1,210 606 289 798 921 15.4 1,117 100 1,017 Outlook 2008 Further volume increases Sustain a good, valuecreating earnings level for the full year, though without matching 2007 Q1 underlying EBITDA to remain practically level with Q4 07 Materials Systems EBIT (underlying) 2004 2005 2006 2007 2003 as reported in 2004 2004 2007 as reported Bayer Investor Handout Q4'07 March 08 (II) Page 78

Key Financials FY 2007 In million FY 2007 FY 2006 Δ Sales 10,435 10,161 + 2.7% EBITDA underlying 1,606 1,677-4.2% EBIT underlying 1,117 1,210-7.7% Gross cash flow 1,228 1,166 + 5.3% Net cash flow 1,147 1,281-10.5% CapEx 889 753 + 18.1% Operating free cash flow 258 528-51.1% R&D 209 227-7.9% Capital invested (average) 7,722 7,489 + 3.1% CFRoI 15.9% 15.6% + 0.3pp Bayer Investor Handout Q4'07 March 08 (II) Page 79 Calendar & Contacts Bayer Investor Handout Q4'07 March 08 (II) Page 80

Calendar of Events Date Event Publication Thursday, April 24, 2008 Friday, April 25, 2008 Wednesday, July 30, 2008 Wednesday, October 29, 2008 Tuesday, May 12, 2009 Investor Conference Call Annual General Meeting Investor Conference Call Investor Conference Call Annual General Meeting First Quarter Results Stockholders Newsletter Second Quarter Results Stockholders Newsletter Third Quarter Results Stockholders Newsletter Bayer Investor Handout Q4'07 March 08 (II) Page 81 Investor Relations Contacts Dr. Alexander Rosar Head of Investor Relations Phone: +49-214-30-81013 E-mail: alexander.rosar@bayer-ag.de Dr. Jürgen Beunink Phone: +49-214-30-65742 E-mail: juergen.beunink@bayer-ag.de Ilia Kürten Phone: +49-214-30-35426 E-mail: ilia.kuerten@bayer-ag.de Judith Nestmann Phone: +49-214-30-66836 E-mail: judith.nestmann@bayer-ag.de Peter Dahlhoff Phone: +49-214-30-33022 E-mail: peter.dahlhoff@bayer-ag.de Ute Menke Phone: +49-214-30-33021 E-mail: ute.menke@bayer-ag.de Dr. Olaf Weber Phone: +49-214-30-33567 E-mail: olaf.weber@bayer-ag.de Bayer Investor Handout Q4'07 March 08 (II) Page 82